| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it will be presenting SP-102 (SEMDEXA™) efficacy and safety data from its Pivotal Phase 3 clinical C.L.E.A.R trial program (Corticosteroid Lumbosacral Epidural Analgesia for Radiculopathy) for sciatica pain management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) on May 5, 2022 in Las Vegas, NV.
The podium presentation will describe the Phase 3 trial, known as the C.L.E.A.R. trial program, randomized 401 lumbosacral radicular pain/sciatica patients at 40 sites across 25 states in the U.S., which is the largest double-blind randomized controlled Phase 3 epidural steroid injection clinical trial in sciatica.
Presenting Author: Prof. Dr. Nebojsa Nick Knezevic, M.D., Ph.D., Professor of Anesthesiology and Surgery, College of Medicine, University of Illinois at Chicago, President of the Illinois Society of Interventional Pain Physicians, Director-at-Large of the North American Society of Neuromodulation, Vice-Chair for Research and Education, Advocate Illinois Masonic Medical Center, Department of Anesthesiology and Pain Management.
The presentation will be during Innovation Summit session at ASIPP on May 5, 2022 at 5:05PM ET to 5:20PM ET, and will describe the outcome of the C.L.E.A.R. trial.
"It has been a while since new drugs have been developed for interventional pain procedures. We are anxiously awaiting a new injectable formulation of viscous gel dexamethasone with extended local effect and its FDA approval for the treatment of radicular pain based on the results of a large randomized multicenter placebo-controlled trial. If approved by the FDA, it will be the first corticosteroid ever approved for epidural injections addressing safety issues with steroid medications that have been used off-label in the past few decades. This could be an important addition to treatment options for these patients, a game-changer," said Prof. Dr. Nebojsa Nick Knezevic, M.D., Ph.D..
Scilex Holding Company and Vickers Vantage Corp. I (NASDAQ:VCKA) ("VCKA"), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, entered into a definitive business combination agreement ("BCA") on March 17, 2022. Upon the closing of the transaction, the combined company (the "Combined Company") will be renamed Scilex Holding Company, and its common stock is expected to be listed on Nasdaq under the ticker symbol "SCLX". The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the third quarter of 2022, is subject to the approval of VCKA's shareholders and the satisfaction or waiver of certain other customary closing conditions.
A corporate presentation describing Scilex's development plans can be found at www.scilexholding.com.
